CGT myth-busting: ‘The process is NOT the product’
Deeper characterization and quality-by-design (QbD) approaches demonstrate the cell and gene therapy space has outgrown the lazy ‘process is the product’ rhetoric, say experts. Journalists and industry alike have clung onto the concept that ‘the process is the product’ when it comes to ce ...
Lonza says a slowdown in funding and clinical trial issues in 2022 led to slower cell and gene therapy (CGT) sales growth compared to 2021.
C ...
Independent technology and product development company TTP Â announced the launch of spin-out company Cellular Origins during Advanced Therapies ...
AGC Biologics’ Bothwell, Washington site is commercially manufacturing Provention Bio’s type 1 diabetes (T1D) monoclonal antibody Tzield (tep ...
Lotte will invest $3 billion over the next seven years to construct three ‘mega’ plants in Korea with a production capacity of 360,000 L.
...
Recent Tweets
-
To everyone at #BiotechWeekBoston - thanks for a great event & see you next year!
4 months ago
-
@Dan5tanton hosting BioProcess Insider’s State of the Industry chat at the spotlight theater here at #BWB2022 https://t.co/UBCZCf1Jng
4 months ago
-
@ADaviesDHCG I couldn’t find a seat, it was so busy! A great talk with some really interesting and helpful talks ma… https://t.co/5b3mjes9tb
4 months ago
-
@ADaviesDHCG on stage at the Spotlight Theater discussing CGT capacity & demand #BWB2022 https://t.co/d5T0KYm7mp
4 months ago
